Cargando…

A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia

BACKGROUND: In infants and young children, the clinical decision to apply glucocorticoids to severe Mycoplasma pneumoniae pneumonia (SMPP) is more an empirical choice with reference to clinical symptoms, but the effect is not satisfying. We aimed to explore and identify early predictive indicators o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ruochen, Mao, Song, Shi, Wenjing, Wu, Liangxia, Zhang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173868/
https://www.ncbi.nlm.nih.gov/pubmed/35685073
http://dx.doi.org/10.21037/tp-22-139
_version_ 1784722111254757376
author Zhu, Ruochen
Mao, Song
Shi, Wenjing
Wu, Liangxia
Zhang, Jianhua
author_facet Zhu, Ruochen
Mao, Song
Shi, Wenjing
Wu, Liangxia
Zhang, Jianhua
author_sort Zhu, Ruochen
collection PubMed
description BACKGROUND: In infants and young children, the clinical decision to apply glucocorticoids to severe Mycoplasma pneumoniae pneumonia (SMPP) is more an empirical choice with reference to clinical symptoms, but the effect is not satisfying. We aimed to explore and identify early predictive indicators of ideal response to glucocorticoids treatment in SMPP in infants and young children. METHODS: We retrospectively reviewed the data of 59 patients, which met the age range and diagnostic criteria, admitted to Department of Pediatrics, the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, from January to December 2017. Patients were divided into a glucocorticoid treatment group and a normal treatment group according to whether glucocorticoid treatment was used, and the difference in therapeutic effectiveness was compared between two groups. The glucocorticoid treatment group was further subdivided into effective versus ineffective treatment groups dependent on the difference of glucocorticoid treatment effect in main clinical symptoms improvement. We obtained the test value of biomarkers by ELISA, and identified several specific indicators with significantly different expressions in the early stage by independent sample t-tests and calculated their cut-off values by ROC curve. RESULTS: Thirty-one SMPP patients who received glucocorticoid treatment were divided into effective and ineffective treatment groups according to the clinical improvements shown on different days of glucocorticoid use. The expression of two markers, interleukin-18 (IL-18) and interferon-γ (IFN-γ), were significantly different in cases showing improvement in the early stage of SMPP (P<0.05), and the cut-off values for IL-18 (218.19 pg/mL, AUC =0.581, sensitivity =0.909, 1-specificity =0.786) and IFN-γ (11.24 pg/mL, AUC =0.566, sensitivity =0.905, 1-specificity =0.795) were identified. CONCLUSIONS: The expressions of IL-18 and IFN-γ in the early stage of SMPP might suggest their predictive effect of early application of glucocorticoid for effective treatment of SMPP in infants and young children. Further study with larger sample size will be carried on in the future.
format Online
Article
Text
id pubmed-9173868
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-91738682022-06-08 A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia Zhu, Ruochen Mao, Song Shi, Wenjing Wu, Liangxia Zhang, Jianhua Transl Pediatr Original Article BACKGROUND: In infants and young children, the clinical decision to apply glucocorticoids to severe Mycoplasma pneumoniae pneumonia (SMPP) is more an empirical choice with reference to clinical symptoms, but the effect is not satisfying. We aimed to explore and identify early predictive indicators of ideal response to glucocorticoids treatment in SMPP in infants and young children. METHODS: We retrospectively reviewed the data of 59 patients, which met the age range and diagnostic criteria, admitted to Department of Pediatrics, the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, from January to December 2017. Patients were divided into a glucocorticoid treatment group and a normal treatment group according to whether glucocorticoid treatment was used, and the difference in therapeutic effectiveness was compared between two groups. The glucocorticoid treatment group was further subdivided into effective versus ineffective treatment groups dependent on the difference of glucocorticoid treatment effect in main clinical symptoms improvement. We obtained the test value of biomarkers by ELISA, and identified several specific indicators with significantly different expressions in the early stage by independent sample t-tests and calculated their cut-off values by ROC curve. RESULTS: Thirty-one SMPP patients who received glucocorticoid treatment were divided into effective and ineffective treatment groups according to the clinical improvements shown on different days of glucocorticoid use. The expression of two markers, interleukin-18 (IL-18) and interferon-γ (IFN-γ), were significantly different in cases showing improvement in the early stage of SMPP (P<0.05), and the cut-off values for IL-18 (218.19 pg/mL, AUC =0.581, sensitivity =0.909, 1-specificity =0.786) and IFN-γ (11.24 pg/mL, AUC =0.566, sensitivity =0.905, 1-specificity =0.795) were identified. CONCLUSIONS: The expressions of IL-18 and IFN-γ in the early stage of SMPP might suggest their predictive effect of early application of glucocorticoid for effective treatment of SMPP in infants and young children. Further study with larger sample size will be carried on in the future. AME Publishing Company 2022-05 /pmc/articles/PMC9173868/ /pubmed/35685073 http://dx.doi.org/10.21037/tp-22-139 Text en 2022 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhu, Ruochen
Mao, Song
Shi, Wenjing
Wu, Liangxia
Zhang, Jianhua
A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia
title A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia
title_full A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia
title_fullStr A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia
title_full_unstemmed A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia
title_short A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia
title_sort prediction study of il-18 and ifn-γ in glucocorticoid treatment response in infants and young children with severe mycoplasma pneumoniae pneumonia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173868/
https://www.ncbi.nlm.nih.gov/pubmed/35685073
http://dx.doi.org/10.21037/tp-22-139
work_keys_str_mv AT zhuruochen apredictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT maosong apredictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT shiwenjing apredictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT wuliangxia apredictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT zhangjianhua apredictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT zhuruochen predictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT maosong predictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT shiwenjing predictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT wuliangxia predictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia
AT zhangjianhua predictionstudyofil18andifnginglucocorticoidtreatmentresponseininfantsandyoungchildrenwithseveremycoplasmapneumoniaepneumonia